Meta-analysisindependent cross-checkabstract only checked I-ODD-14 standard review
Semaglutide and NAION: pooled analysis 1
Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.
Overview
Abdelaal A et al.. Ophthalmology 2026 · PMID 41692115 · DOI 10.1016/j.ophtha.2026.02.013
No consistent overall increase found; possible increase in diabetes patients; evidence weak.
Does the study support the specific claim? Partly · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Semaglutide vs non-GLP-1 RA therapy and NAION
- How was the study done?
Systematic review and meta-analysis of observational studies with GRADE
- How many people, animals or samples were studied?
6 studies; 4,831,654 participants; Adults on semaglutide or comparators
- What was actually found?
aHR 1.63 (n.s.).
- How large was the observed effect?
aHR 1.63 (0.88-2.39)
- What do the results mean in everyday life?
Risk uncertain.
- What are the study's limitations?
Observational inputs; Extreme heterogeneity
- What does it say about Elawady's specific claim?
Limits C-ODD-10.
- Do the results apply to Germany and Europe?
Includes multinational data.
- What can explicitly not be concluded from this study?
Causation.
Scientific in-depth review
1. Full reference
- Authors
- Abdelaal A et al.
- Journal
- Ophthalmology
- Year
- 2026
- Identifier
- PMID 41692115 DOI 10.1016/j.ophtha.2026.02.013
- Verification
- verified – PubMed efetch 2026-10-25 (this agent)
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
Semaglutide vs non-GLP-1 RA therapy and NAION
3. Study design and population
- Study design
- Meta-analysis – Systematic review and meta-analysis of observational studies with GRADE
- Population
Adults on semaglutide or comparators
- Country
International
- Period
To August 2025
- Sample size
6 studies; 4,831,654 participants
- Inclusion and exclusion criteria
As described in the abstract; details not available in abstract.
4. Methods and endpoints
- Exposure / intervention
Semaglutide
- Comparator
Non-GLP-1 RA therapies
- Endpoints
NAION
- Statistical methods
Random effects; GRADE
5. Actual results
- Results
Pooled OR 2.44 (0.59-10.15; I2 99%; very low certainty); pooled aHR 1.63 (0.88-2.39; low certainty); excluding one study aHR 1.92 (1.03-2.81); T2D aHR 1.70 (1.10-2.64); obesity 0.47 (0.19-1.13).
- Absolute risks
not reported
- Authors' conclusion
Pooled adjusted evidence does not demonstrate a consistent overall increase; low to very low certainty; causality cannot be established.
6. Strengths
- PROSPERO-registered
- GRADE
7. Weaknesses
- Observational inputs
- Extreme heterogeneity
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Heterogeneous observational data.
9. Assessment of the statistical interpretation
Fragile estimates.
10. Relevance to the specific claim
Limits C-ODD-10.
11. Independent contrary findings
12. Transferability to Germany and Europe
Includes multinational data.
13. Overall methodological judgement
Uncertain signal.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | low |
| Directness | direct |
| Reproducibility | partly replicated |
| Consistency with the overall evidence | inconsistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
None beyond those stated.
15. Linked fact checks
- Semaglutide (Ozempic) is associated with a markedly higher risk of non-arteritic anterior ischaemic optic neuropathy (NAION), which can cause blindness (HR 4.28 in diabetes). – Studies contradicting or limiting the claim